Read more at: Human Health
Employing high-resolution X-rays to diagnose breast cancer – PSI researchers nominated for the European Inventor Award.
PSI researchers have developed a new substance that disables a vital protein in the cell skeleton.
PSI is involved in the development of a breath test that can be used to diagnose asthma. Imad El Haddad explains why such a test could be extremely useful – especially for children.
The test identifies different virus variants and improves disease prognosis.
The European Research Council approves PSI projects for the development of a quantum computer and brain research worth about 5 million euros.
PSI scientists have shed light on the structure of an important component of the eye: CNG ion channels whose job is to relay optical signals to the brain.
This gallery presents five people who have been treated at the PSI's Center for Proton Therapy.
Kantonsspital Baden and the Paul Scherrer Institute PSI have signed a cooperation agreement.
In partnership with Roche, PSI scientists are developing new, potentially more efficient catalysts for manufacturing active substances for drug therapies.
25 November 1996: a world first for PSI’s Center for Proton Therapy in treating a cancer patient using the spot-scanning technique.
On 9 November 2021 a lung cancer patient was given proton therapy at the Paul Scherrer Institute PSI for the first time in Switzerland.
PSI researchers identify potential active agent against several unicellular parasites – including the pathogens that cause malaria and toxoplasmosis.
PSI researchers have developed a new method to attach proteins to the surface of virus-like particles.
The University Hospital of Zurich uses proteins made at PSI for Europe’s first large-scale serology study on coronavirus prevalence in Switzerland.
Crystal structure analysis, computer models, cell cultures – to pursue research on Sars-CoV-2, PSI is exploring many avenues. An overview.
A research consortium has deciphered the mechanism of CCR5 receptor activation, providing insights for the development of CCR5 drug antagonists for AIDS, cancer, and inflammatory diseases.
Researchers at Goethe University Frankfurt, in cooperation with the PSI have probably discovered another, previously unknown mechanism of action of the antiviral remdesivir.
Using a combination of computer simulations and laboratory experiments, PSI researchers have identified new binding sites for active agents on the vital protein tubulin.